The Latest Breaking News from FDA

A midstage study of the psychedelic drug LSD showed positive results for easing symptoms in people with generalized anxiety disorder

On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.’s (NASDAQ:AGIO) supplemental New Drug Application (sNDA) of Pyrukynd (mitapivat) for adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025. 

Two California-based companies accuse the state of government overreach for banning the sale of their products for the next two years.

China-based drugmakers that once fueled a surge of copycat weight-loss treatments in the U.S. are now pivoting to generics of Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly's (NYSE:LLY) Zepbound as regulators tighten rules on compounded medicines.

Consumer protection police raided two warehouses in Bangkok’s Bang Khun Thian district and seized goods smuggled from China worth over 10 million baht.

Offit, long-serving vaccine scientist, says he was not given a reason for dismissal after initially being offered extension

In a move praised by RFK Jr, the FDA approved a new shot, but only for some people – here’s what to know about who can get them, and where

An undeclared allergen is one of the most serious and common reasons for a food recall. A simple mistake on the ingredient label can have life-threatening consequences for a person with a severe food allergy. In 2025, the FDA has already issued numerous recalls for popular snack foods that were…

Imagine shelling out extra money to give your pet the “best of the best,” only to learn the food could be the very thing harming them.